Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jul 14;100(5):525-34.
doi: 10.1016/j.physbeh.2010.03.018. Epub 2010 Apr 8.

The renin angiotensin system and the metabolic syndrome

Annette D de Kloet  1 , Eric G Krause, Stephen C Woods
Affiliations
Review

The renin angiotensin system and the metabolic syndrome

Annette D de Kloet et al. Physiol Behav. .

Abstract

The renin angiotensin system (RAS; most well-known for its critical roles in the regulation of cardiovascular function and hydromineral balance) has regained the spotlight for its potential roles in various aspects of the metabolic syndrome. It may serve as a causal link among obesity and several co-morbidities. Drugs that reduce the synthesis or action of angiotensin-II (A-II; the primary effector peptide of the RAS) have been used to treat hypertension for decades and, more recently, clinical trials have determined the utility of these pharmacological agents to prevent insulin resistance. Moreover, there is evidence that the RAS contributes to body weight regulation by acting in various tissues. This review summarizes what is known of the actions of the RAS in the brain and throughout the body to influence various metabolic disorders. Special emphasis is given to the role of the RAS in body weight regulation. The paper represents an invited review by a symposium, award winner or keynote speaker at the Society for the Study of Ingestive Behavior [SSIB] Annual Meeting in Portland, July 2009.

PubMed Disclaimer

Figures

Figure 1
Figure 1. The classical (endocrine) renin angiotensin system
A-II is formed from liver-synthesized angiotensinogen via a series of proteolytic cleavage events. Angiotensinogen is first cleaved by the rate-limiting enzyme renin (formed in and secreted from the kidney) into A-I. A-I is then processed by ACE (from the lung) into A-II. Circulating A-II activates AT1 and AT2 receptors in various tissues, such as the brain, adrenal and vascular tissue to modulate cardiovascular and hydromineral homeostasis.
Figure 2
Figure 2. The updated renin angiotensin system
In addition to the classical enzymatic cascade for A-II synthesis, there are several alternative pathways for A-II synthesis. Binding of prorenin to the (pro)renin receptor activates intracellular signaling pathways and also allows for the conversion of angiotensinogen to A-I by the prorenin/(pro)renin receptor complex. There are also alternative active angiotensin peptides, including angiotensin (1–7) and angiotensin-IV that are formed by other enzymes. These peptides activate the Mas and angiotensin type-4 (AT4; insulin-regulated aminopetidase [IRAP]) receptors, respectively.
Figure 3
Figure 3. Proposed energy and glucose homeostasis-modulatory actions of A-II in various tissues
These tissues also contain local RASs, indicating that A-II’s influence may be autocrine, paracrine or endocrine.
See this image and copyright information in PMC

References

    1. James WPT. The epidemiology of obesity: the size of the problem. Journal of Internal Medicine. 2008;263(4):336–352. - PubMed
    1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of Overweight and Obesity in the United States, 1999–2004. JAMA. 2006;295(13):1549–1555. - PubMed
    1. de Kloet AD, Krause EG, Kim DH, Sakai RR, Seeley RJ, Woods SC. The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis. Endocrinology. 2009;150(9):4114–23. - PMC - PubMed
    1. Jayasooriya AP, Mathai ML, Walker LL, Begg DP, Denton DA, Cameron-Smith D, Egan GF, McKinley MJ, Rodger PD, Sinclair AJ, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance. Proceedings of the National Academy of Sciences. 2008;105(18):6531–6536. - PMC - PubMed
    1. Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, Fukamizu A, Negrel R, Ailhaud G, Teboul M. Angiotensinogen-Deficient Mice Exhibit Impairment of Diet-Induced Weight Gain with Alteration in Adipose Tissue Development and Increased Locomotor Activity. Endocrinology. 2001;142(12):5220–5225. - PubMed